Provided by Tiger Fintech (Singapore) Pte. Ltd.

SHANDONG XINHUA

5.440
+0.0200.37%
Volume:440.00K
Turnover:2.39M
Market Cap:3.75B
PE:7.42
High:5.460
Open:5.410
Low:5.410
Close:5.420
Loading ...

Shandong Xinhua Pharmaceutical Gets China Nod for Eszolam Marketing License Transfer

MT Newswires Live
·
15 Apr

Xinhua Pharmaceutical Gets Nod to Market Pentazocine Injection

MT Newswires Live
·
12 Mar

Chinese Regulator Issues Drug Registration Certificate for Shandong Xinhua Pharmaceutical's Diabetes Tablets

MT Newswires Live
·
21 Jan

Shandong Xinhua Pharmaceutical (HKG:719) Has A Pretty Healthy Balance Sheet

Simply Wall St.
·
14 Jan

Shandong Xinhua Pharmaceutical's Pain Drug Passes Chinese Regulator's Consistency Evaluation

MT Newswires Live
·
10 Jan

Shandong Xinhua Pharmaceutical to Renew License Agreement for Trademark Xinhua

MT Newswires Live
·
31 Dec 2024

Shandong Xinhua Pharmaceutical Eyes Stake in Nutritional Oil Refining Firm

MT Newswires Live
·
10 Dec 2024

Shandong Xinhua Pharmaceutical Unit's Infection Drug Passes Chinese Regulator's Consistency Evaluation

MT Newswires Live
·
03 Dec 2024

Shandong Xinhua Pharmaceutical Gets Marketing Go-Ahead for Hyperphosphatemia Drug from FDA

MT Newswires Live
·
26 Nov 2024

Shandong Xinhua Pharmaceutical Gets Drug Registration Certificate for Hyperuricemia Drug by Chinese Regulator

MT Newswires Live
·
11 Nov 2024

Xinhua Pharma's Calcium Deficiency Drug Gets Generic Status in China

MT Newswires Live
·
05 Nov 2024

Shandong Xinhua Pharmaceutical Unit's Antibiotic Passes China Generics Evaluation

MT Newswires Live
·
04 Nov 2024

Chinese Regulator Green Lights Shandong Xinhua Pharmaceutical's Marketing Application for Pain Relief Drug

MT Newswires Live
·
04 Nov 2024

Shandong Xinhua Pharmaceutical's Attributable Profit Falls 12% in January-September

MT Newswires Live
·
30 Oct 2024

Shandong Xinhua Pharmaceutical Gets FDA Approval for Hyperphosphatemia Drug

MT Newswires Live
·
28 Oct 2024